In this review:
This publication is intended as an educational resource for healthcare professionals. It reviews risk factors, incidence and burden associated with meningococcal disease, focusing on the New Zealand setting. Vaccines available for meningococcal disease in New Zealand are discussed, including an in-depth review of 4CMenB (BEXSERO®), the only vaccine available in this country for group B disease.
Download PDF